Aphria Inc. and SecureCom Mobile Inc. are pleased to announce the successful first step of their previously announced US expansion strategy.
Aphria is pleased to announce that the Company has received a license amendment from Health Canada that provides Aphria with additional production space of 57,000 square feet, as part of its Part II expansion at its facility in Leamington, Ontario.
Aphria today unveiled its 'Seed to Sale Certified' quality promise as part of its long-standing commitment to the cultivation and production of clean and safe medical cannabis.
Aphria announced today that it has secured a $100 million raise, including a $75 million bought deal equity financing and $25 million in debt financing through a five–year term loan.
Tetra Bio-Pharma Inc. and Aphria Inc. announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Aphria Inc., a Health Canada Licensed Producer of medical cannabis products, comments on the proposed Cannabis Act announced today..
Aphria Inc. today reported its third quarter results, for the three and nine months ended February 28, 2017.
Aphria Inc. and MassRoots, Inc. are pleased to announce the early exercise of warrants by Aphria at US$0.90 per share for total proceeds to MassRoots of US$450,000.
Aphria through its subsidiary Aphria (Arizona) Inc., is pleased to announce that it made an additional investment of $3 million (USD) in Copperstate Farms Investors, LLC (“Investors”).
Aphria today announced that the common shares (the “Common Shares”) of the Company will begin trading on the Toronto Stock Exchange (“TSX”) as of the open of the market on March 22, 2017.
In light of recent media coverage, Aphria Inc. issued the following statement with respect to its ongoing commitment to providing pharmaceutical-grade cannabis that is free of chemical pesticides.